Nephrology

Most relevant publications of the last few years:

Research group Prof. T. Fehr

Fehr T, Lucas CL, Kurtz J, Onoe T, Zhao G, Hogan T, Vallot C, Rao A, Sykes M. A CD8 T cell-intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo. Blood 2010 (epub ahead).

Starke A, Lindenmeyer MT, Segerer S, Neusser MA, Rüsi B, Schmid DM, Cohen CD, Wüthrich RP, Fehr T, Waeckerle-Men Y: Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int. 78(1):38-47 (2010).

Fehr T, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment for chronic antibody-mediated kidney allograft rejection. Transplantation 87:1837-1841 (2009).

Valli PV, Puga Yung G, Schulz-Huotari C, Kaup N, Güngör T, Ambühl PM, Weber M, Fehr T, Schanz U, Seebach JD, Stussi G. Changes of circulating antibody levels induced by ABO antibody absorption for ABO Incompatible Kidney Transplantation. Am J Transplant. 9:1072-1080 (2009).

Fehr T, Haspot F, Mollov J, Chittenden M, Hogan T, Sykes M. Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells and MHC class II. J Immunol. 181:165-173 (2008).

Fehr T, Wang S, Haspot F, Kurtz J, Blaha P, Hogan T, Chittenden, Wekerle T, Sykes M. Rapid, deletional peripheral CD8 T cell tolerance induced by allogeneic bone marrow: role of donor class II MHC and B cells. J Immunol. 181:4371-4380 (2008).

Haspot F, Fehr T, Gibbons C, Zhao G, Hogan T, Honjo T, Freeman G, Sykes M. Peripheral deletional tolerance of alloreactive CD8, but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood. 112:2149-2155 (2008).

Fehr,T. & Sykes,M. Clinical experience with mixed chimerism to induce transplantation tolerance (Review). Transpl Int 21, 1118-1135 (2008).

Fudaba,Y., Spitzer,T.R., Shaffer,J., Kawai,T., Fehr,T., Delmonico,F., Preffer,F., Tolkoff-Rubin,N., Dey,B., Saidman,S.L., Kraus,A., Bonnefoix,T., McAfee,S., Power,K., Kattleman,K., Colvin,R.B., Sachs,D.H., Cosimi,A.B., Sykes,M. Myeloma responses and tolerance following combined kidney and non-myeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant. 6, 2121-2133 (2006).

Fehr,T., Takeuchi,Y., Kurtz,J., Wekerle,T. & Sykes,M. Early regulation of CD8 T cell alloreactivity by CD4(+)CD25(- ) T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8(+) T cells, precluding a role for sustained regulation. Eur J Immunol. 35, :2679-2690 (2005).

Fehr,T. & Sykes,M. Tolerance induction in clinical transplantation (Review). Transpl. Immunol. 13, 117-130 (2004).

Research group PD Dr. A. Serra

Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 363(9):820-9 (2010).

Pavik I, Jaeger Ph., Kistler AD., Poster D., Krauer F, Cavelti-Weder C, Rentsch K, Wüthrich RP and Serra AL. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int. (2010)

Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol. Am J Physiol Renal Physiol. 297(6):F1597-605

Kistler AD, Poster D, Wüthrich RP, Serra AL. Hydronephrosis in autosomal dominant polycystic kidney disease. Kidney Int. 76(12):1297 (2009).

Serra AL, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. Nephrol Dial Transplant. 24(11):3334-42 (2009).

Kistler AD, Mischak H, Poster D, Dakna M, Wüthrich RP and Serra AL. Identification of a unique urinary biomarker profile in autosomal dominant polycystic kidney disease. Kidney Int. 76(1):89-96 (2009).

Poster D, Kistler AD, Krauer F, Blumenfeld JD, Rennert H, Weishaupt D, Wüthrich RP and Serra AL. Kidney function and volume progression in unilateral ADPKD with contralateral renal agenesis or hypoplasia: a case series. Am J Kidney Dis. 54(3):450-8 (2009).

Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP and Serra AL. Increases in kidney volume in Autosomal Dominant Polycystic Kidney Disease can be detected within 6 months, Kidney Int. 75(2):235-41 (2009).

Serra AL, SC Braun, A Starke, R Savoca, M Hersberger, S Russmann, N Corti and RP Wüthrich. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 8(4):803-10 (2008).

Berthier CC, Wahl PR, Le Hir M, Marti HP, Wagner U, Rehrauer H, Wüthrich RP, Serra AL. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of ADPKD. Nephrol Dial Transplant. 23(3):880-9 (2008).